GSK3-beta as a candidate therapeutic target in soft tissue sarcomas

Soft tissue sarcoma (STS) is a predominantly fatal rare malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies. Its therapeutic relevance in STS is unknown. We analyzed the prognostic impact of GSK-3β gene and protein expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbeke, S., Perret, R., Chaire, V., Richard, E., Velasco, V., Giles, F., Cavalcante, L., Italiano, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641200/
https://www.ncbi.nlm.nih.gov/pubmed/34857030
http://dx.doi.org/10.1186/s13045-021-01215-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641200/
https://www.ncbi.nlm.nih.gov/pubmed/34857030
http://dx.doi.org/10.1186/s13045-021-01215-x

Ejemplares similares